Literature DB >> 14605200

Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism.

Marco Cassone1, Pietro Serra, Francesca Mondello, Antonietta Girolamo, Sandro Scafetti, Eleonora Pistella, Mario Venditti.   

Abstract

We report an outbreak of Saccharomyces cerevisiae subtype boulardii fungemia among three intensive care unit roommates of patients receiving lyophilized preparations of this fungus. The fungemia was probably due to central venous catheter contamination and resolved after fluconazole treatment. The need for stringent application of proper hygiene when using a probiotic preparation of this organism is emphasized.

Entities:  

Mesh：

Year:  2003        PMID： 14605200      PMCID： PMC262466          DOI： 10.1128/JCM.41.11.5340-5343.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

1.  Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii.

Authors:  M Niault; F Thomas; J Prost; F H Ansari; P Kalfon
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

2.  Saccharomyces fungemia complicating Saccharomyces boulardii treatment in a non-immunocompromised host.

Authors:  B J Rijnders; E Van Wijngaerden; C Verwaest; W E Peetermans
Journal:  Intensive Care Med       Date:  2000-06       Impact factor: 17.440

3.  Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii.

Authors:  S Cesaro; P Chinello; L Rossi; L Zanesco
Journal:  Support Care Cancer       Date:  2000-11       Impact factor: 3.603

4.  [Saccharomyces boulardii fungemia. Apropos of a case].

Authors:  P Zunic; J Lacotte; M Pegoix; G Buteux; G Leroy; B Mosquet; M Moulin
Journal:  Therapie       Date:  1991 Nov-Dec       Impact factor: 2.070

5.  Are live saccharomyces yeasts harmful to patients?

Authors:  R Piarroux; L Millon; K Bardonnet; O Vagner; H Koenig
Journal:  Lancet       Date:  1999-05-29       Impact factor: 79.321

6.  [Saccharomyces boulardii fungemia in a patient with severe burns].

Authors:  M Viggiano; C Badetti; V Bernini; M Garabedian; J C Manelli
Journal:  Ann Fr Anesth Reanim       Date:  1995

7.  Karyotypes of Saccharomyces sensu lato species.

Authors:  R F Petersen; T Nilsson-Tillgren; J Piskur
Journal:  Int J Syst Bacteriol       Date:  1999-10

8.  Saccharomyces boulardii in maintenance treatment of Crohn's disease.

Authors:  M Guslandi; G Mezzi; M Sorghi; P A Testoni
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

9.  Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultra-levura.

Authors:  J Perapoch; A M Planes; A Querol; V López; I Martínez-Bendayán; R Tormo; F Fernández; G Peguero; S Salcedo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-06       Impact factor: 3.267

10.  Seven cases of fungemia with Saccharomyces boulardii in critically ill patients.

Authors:  Thierry Lherm; Claire Monet; Bruno Nougière; Muriel Soulier; Daho Larbi; Christian Le Gall; Daniel Caen; Claire Malbrunot
Journal:  Intensive Care Med       Date:  2002-05-10       Impact factor: 17.440
View more
  38 in total

Review 1.  Hospital-related outbreaks due to rare fungal pathogens: a review of the literature from 1990 to June 2011.

Authors:  E C Repetto; C G Giacomazzi; F Castelli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-03       Impact factor: 3.267

Review 2.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

3.  Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

Authors:  Elaine O Petrof
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01

4.  Use of probiotics in gastrointestinal disorders: what to recommend?

Authors:  Elizabeth C Verna; Susan Lucak
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

5.  Determination of MICING: a new assay for assessing minimal inhibitory concentration for invasive growth.

Authors:  J Zupan; Z Tomičić; P Raspor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-27       Impact factor: 3.267

6.  Saccharomyces boulardii fungemia caused by treatment with a probioticum.

Authors:  Julie Bjerre Thygesen; Henning Glerup; Britta Tarp
Journal:  BMJ Case Rep       Date:  2012-03-27

7.  Trends in Clostridium difficile Disease: Epidemiology and Intervention.

Authors:  David J Riddle; Erik R Dubberke
Journal:  Infect Med       Date:  2009

Review 8.  Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review.

Authors:  Jennifer M Tung; Lisa R Dolovich; Christine H Lee
Journal:  Can J Gastroenterol       Date:  2009-12       Impact factor: 3.522

Review 9.  The emerging world of the fungal microbiome.

Authors:  Gary B Huffnagle; Mairi C Noverr
Journal:  Trends Microbiol       Date:  2013-05-17       Impact factor: 17.079

10.  Differential Flo8p-dependent regulation of FLO1 and FLO11 for cell-cell and cell-substrate adherence of S. cerevisiae S288c.

Authors:  Lars Fichtner; Florian Schulze; Gerhard H Braus
Journal:  Mol Microbiol       Date:  2007-12       Impact factor: 3.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.